ACAD
36.53
-0.45
-1.22%
AEMD
1.798
-0.152
-7.7744%
APRI
1.75
-0.02
-1.13%
ARNA
24.53
+0.22
+0.90%
ATEC
2.117
-0.103
-4.6532%
CNAT
5.6
-0.09
-1.58%
CRXM
0.163
0.00
0.00%
CYTX
0.346
+0.006
+1.765%
DXCM
69.46
+0.2
+0.29%
GNMK
9.4
-0.25
-2.59%
HALO
16.42
-0.3
-1.79%
ILMN
204.95
-4.45
-2.13%
INNV
0.096
-0.003
-3.3266%
INO
6.07
+0.07
+1.17%
ISCO
1.53
-0.01
-0.65%
ISIS
57.56
0.00
0.00%
LGND
136.18
+1.03
+0.76%
LPTN
2.93
-2.93
-100.00%
MBVX
0.71
+0.03
+4.4124%
MEIP
2.69
0.00
0.00%
MNOV
5.47
-0.1
-1.80%
MRTX
10.55
-0.25
-2.31%
MSTX
0.13
-0.01
-5.28%
NBIX
56.34
-0.35
-0.62%
NUVA
53.515
-4.285
-7.413%
ONCS
0.99
0.00
-0.50%
ONVO
2.025
+0.035
+1.759%
OREX
2.33
-0.01
-0.43%
OTIC
3.25
-0.15
-4.41%
QDEL
43.55
+2.64
+6.45%
RCPT
231.96
0.00
0.00%
RGLS
1.32
-0.01
-0.75%
RMD
79.45
-0.08
-0.10%
SCIE
0
0.00
0.00%
SPHS
2.334
+0.012
+0.5254%
SRNE
1.75
-0.1
-5.41%
TROV
0.67
-0.03
-4.29%
VICL
2.4
-0.05
-2.04%
VOLC
18
0.00
0.00%
ZGNX
14.55
+0.3
+2.11%
ACAD
36.53
-0.45
-1.22%
AEMD
1.798
-0.152
-7.7744%
APRI
1.75
-0.02
-1.13%
ARNA
24.53
+0.22
+0.90%
ATEC
2.117
-0.103
-4.6532%
CNAT
5.6
-0.09
-1.58%
CRXM
0.163
0.00
0.00%
CYTX
0.346
+0.006
+1.765%
DXCM
69.46
+0.2
+0.29%
GNMK
9.4
-0.25
-2.59%
HALO
16.42
-0.3
-1.79%
ILMN
204.95
-4.45
-2.13%
INNV
0.096
-0.003
-3.3266%
INO
6.07
+0.07
+1.17%
ISCO
1.53
-0.01
-0.65%
ISIS
57.56
0.00
0.00%
LGND
136.18
+1.03
+0.76%
LPTN
2.93
-2.93
-100.00%
MBVX
0.71
+0.03
+4.4124%
MEIP
2.69
0.00
0.00%
MNOV
5.47
-0.1
-1.80%
MRTX
10.55
-0.25
-2.31%
MSTX
0.13
-0.01
-5.28%
NBIX
56.34
-0.35
-0.62%
NUVA
53.515
-4.285
-7.413%
ONCS
0.99
0.00
-0.50%
ONVO
2.025
+0.035
+1.759%
OREX
2.33
-0.01
-0.43%
OTIC
3.25
-0.15
-4.41%
QDEL
43.55
+2.64
+6.45%
RCPT
231.96
0.00
0.00%
RGLS
1.32
-0.01
-0.75%
RMD
79.45
-0.08
-0.10%
SCIE
0
0.00
0.00%
SPHS
2.334
+0.012
+0.5254%
SRNE
1.75
-0.1
-5.41%
TROV
0.67
-0.03
-4.29%
VICL
2.4
-0.05
-2.04%
VOLC
18
0.00
0.00%
ZGNX
14.55
+0.3
+2.11%
Home » Archive by Category

Syndication

Symic Bio to Present at the Ladenburg Thalmann 2017 Annual Healthcare Conference

September 18, 2017 – 6:00 am

SAN FRANCISCO, Sept. 18, 2017 /PRNewswire/ — Symic Bio, a biopharmaceutical company developing novel matrix regulators, today announced that Ken Horne, Chief Executive Officer, will present an overview of the company pipeline at the Ladenburg Thalmann 2017 Healthcare Conference in New York.

Presentation details are as follows:

                Date:                     Tuesday, Sept. 26, 2017

                Time:                     11 a.m. EDT

                Location:               Sofitel New York Hotel, New York

About Symic Bio

Symic Bio is a biopharmaceutical company developing novel matrix regulators, a new category of therapeutics focused on matrix biology. These therapeutics, with potential applications in a wide variety of disease states, are inspired by naturally occurring macromolecules that play key regulatory roles within the extracellular matrix. Symic Bio currently has two clinical candidates: SB-030, which is targeting the prevention of peripheral vascular disease, and SB-061, directed at disease modification and pain management in the treatment of osteoarthritis. In addition, Symic Bio is investigating applications in the areas of fibrosis, oncology and diseases of the central nervous system. For additional information please visit the company’s website at www.symic.bio, LinkedIn page at www.linkedin.com/company/symic-bio or follow on Twitter at www.twitter.com/symicbio.

 

View original content:http://www.prnewswire.com/news-releases/symic-bio-to-present-at-the-ladenburg-thalmann-2017-annual-healthcare-conference-300519442.html

SOURCE Symic Bio

Akili, Emulate, Ginkgo & More: The Innovation at the Intersection Award Finalists

September 18, 2017 – 4:00 am

Research that happens at the intersection of different fields can lead to new innovations that tackle pressing problems in the life sciences. This year’s finalists in the Innovation at the…

[[Click headline to continue reading.]]

Abide Therapeutics Appoints Dr. Sapna Srivastava As Chief Financial and Strategy Officer

September 18, 2017 – 3:00 am

SAN DIEGO, Sept. 18, 2017 /PRNewswire/ — Abide Therapeutics, a developer of innovative pharmaceuticals, announced today the appointment of Sapna Srivastava, Ph.D., to the position of Chief Financial and Strategy Officer. Dr. Srivastava brings to Abide more than 15 years of experience with a strong background in the biopharmaceutical industry and Wall Street.

“At Abide Therapeutics we are absolutely committed to discovering and developing novel serine hydrolase inhibitors that have a profound effect on improving patients’ lives.  Our success to date in advancing our lead program, ABX-1431, into the clinic to treat diseases like Tourette Syndrome, neuromyelitis optica, and spasticity in multiple sclerosis validates the potential of the Abide platform and enables us to attract outstanding people, exemplified by our hiring of Dr. Sapna Srivastava,” said Alan Ezekowitz, MBChB, DPhil, CEO and President of Abide Therapeutics.  “We are at an exciting time in the life cycle of Abide Therapeutics, and expanding our senior leadership team with an individual like Sapna, who possesses such a broad and relevant set of work experiences, will contribute immensely to the implementation of our strategy.”

Dr. Srivastava has more than 15 years of experience as a senior executive in the biopharmaceutical industry and on Wall Street.  Most recently, Dr. Srivastava held the position of Chief Financial and Strategy Officer at Intellia Therapeutics, where she played a key role in equity financings including taking the company public, and in setting the strategic direction of the company.  Prior to that role, Dr. Srivastava spent over a decade on Wall Street as a Senior Biotechnology Analyst for Goldman Sachs, Morgan Stanley and ThinkEquity Partners, LLC. She began her career as a research associate at J.P. Morgan.  Dr. Srivastava has also served as an independent strategic advisor for biotechnology companies focused on developing therapeutics, and co-founded a neuroscience-focused biotechnology company. Dr. Srivastava earned her Ph.D. in neuroscience from the New York University School of Medicine and her B.S. in Biology from St. Xavier’s College at the University of Mumbai.

“Abide is a remarkably unique combination of innovative science, world-class talent, and a company-wide shared commitment to positively impact the lives of people suffering from serious diseases. I feel privileged to be part of the team and look forward to contributing to the significant advances being made by Abide,” said Dr. Srivastava.

About Abide Therapeutics

Abide Therapeutics combines an innovative discovery platform and a library of proprietary small molecules to address biological pathways with therapeutics that enhance the body’s normal physiological response to disease. The platform enables Abide to quickly and efficiently identify, modify and validate small molecule inhibitors that target serine hydrolases, a highly relevant but under-explored class of enzymes. Abide’s initial area of focus is on addressing neurological disorders with limited treatment options through the endocannabinoid pathway.

Abide has offices in San Diego, California and Princeton, New Jersey. To learn more, visit www.abidetx.com.

Investor Contact:
Chris Brinzey
Westwicke Partners
Tel: 339-970-2843
Chris.brinzey@westwicke.com

 

View original content with multimedia:http://www.prnewswire.com/news-releases/abide-therapeutics-appoints-dr-sapna-srivastava-as-chief-financial-and-strategy-officer-300520998.html

SOURCE Abide Therapeutics

Oncolytics Biotech® Announces Successful End-of-Phase 2 Meeting with FDA for REOLYSIN® in Metastatic Breast Cancer

September 18, 2017 – 3:00 am

Outcome supports focus on HR+/HER2- patient group that reported an
effective doubling of median overall survival from 10.8 to 21.0 months

CALGARY and SAN DIEGO, Sept. 18, 2017 /PRNewswire/ – Oncolytics Biotech® Inc. (TSX: ONC) (OTCQX: ONCYF) (Oncolytics or the Company), a biotech company developing REOLYSIN® (pelareorep) a first-in-class, intravenously delivered immuno-oncolytic virus that activates the innate and adaptive immune systems, today announced a successful End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) for REOLYSIN in combination with paclitaxel, for the treatment of hormone receptor positive, HER2 receptor negative (HR+/HER2-) metastatic breast cancer (mBC) patients. The purpose of the meeting was to discuss the preclinical and clinical programs, including the design of the phase 3 registration study to support a future Biologics License Application (BLA) submission in the U.S.

“The FDA’s feedback and positive End-of-Phase 2 meeting outcome support our proposed target patient population of HR positive/HER2 negative metastatic breast cancer patients for our registration study,” said Dr. Matt Coffey, President and CEO of Oncolytics Biotech. “With statistically significant and clinically compelling overall survival data, Fast Track designation and now clear guidance from the FDA, we are focused on finalizing the adaptive study design that will include approximately four hundred patients with a pre-determined interim analysis. Importantly, the FDA provided guidance that if the study achieves its primary endpoint, then it will be the only study required for BLA approval.  The design of the study and this FDA guidance will also continue to drive our partnering process.”   

Oncolytics’ proposed target population for its phase 3 study of pelareorep is patients with HR+/HER2- mBC, which represents approximately 73 percent of metastatic breast cancer cases that have limited treatment options that offer survival benefit. Details of the pivotal phase 3 registration study will be made available following evaluation and completion of discussions with clinical advisors, European regulators and potentially partners.

About Metastatic Breast Cancer
Metastatic breast cancer, also known as advanced or Stage 4 breast cancer, has spread to other parts of the body.  Most commonly the lungs, liver, bones or brain.  The disease affects over 154,000 women in the United States and according to the American Cancer Society, has a five-year survival rate of just 22 percent. Significantly lower than stage 3, with a five-year relative survival rate of 72 percent and stage 2, with a five-year survival rate over 90 percent.

About REOLYSIN
REOLYSIN® is a non-pathogenic, proprietary isolate of the unmodified reovirus: a first-in-class intravenously delivered immuno-oncolytic virus for the treatment of solid tumors and hematological malignancies. The compound induces selective tumor lysis and promotes an inflamed tumor phenotype through innate and adaptive immune responses to treat a variety of cancers.

About Oncolytics Biotech Inc.
Oncolytics is a biotechnology company developing REOLYSIN, an intravenously delivered immuno-oncolytic virus. The compound induces selective tumor lysis and promotes an inflamed tumor phenotype through innate and adaptive immune responses to treat a variety of cancers. Oncolytics’ clinical development program emphasizes three pillars: chemotherapy combinations to trigger selective tumor lysis; immuno-therapy combinations to produce adaptive immune responses; and immune modulator (IMiD) combinations to facilitate innate immune responses. Oncolytics is currently planning its first registration study in metastatic breast cancer, as well as studies in combination with checkpoint inhibitors as well as targeted and IMiD therapies in solid and hematological malignancies. For further information about Oncolytics, please visit: www.oncolyticsbiotech.com.

This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including the Company’s belief as to the potential of REOLYSIN® as a cancer therapeutic; the Company’s expectations as to the success of its research and development programs in 2017 and beyond, the Company’s planned operations, the value of the additional patents and intellectual property; the Company’s expectations related to the applications of the patented technology; the Company’s expectations as to adequacy of its existing capital resources; the design, timing, success of planned clinical trial programs; and other statements related to anticipated developments in the Company’s business and technologies involve known and unknown risks and uncertainties, which could cause the Company’s actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of REOLYSIN as a cancer treatment, the success and timely completion of clinical studies and trials, the Company’s ability to successfully commercialize REOLYSIN, uncertainties related to the research and development of pharmaceuticals, uncertainties related to the regulatory process and general changes to the economic environment. Investors should consult the Company’s quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake to update these forward-looking statements, except as required by applicable laws.

SOURCE Oncolytics Biotech Inc.

Protein Conjugation Chemist

September 16, 2017 – 10:56 am

Protein Conjugation Chemist
Location: San Diego
Cell IDx, Inc. (www.cellidx.com) develops and markets protein conjugates for a first-in-class multiplex immunofluorescence (mxIF) detection technology that can for the first time simultaneously detect …

Protein Conjugation Chemist

September 16, 2017 – 10:56 am

Protein Conjugation Chemist
Location: San Diego
Cell IDx, Inc. (www.cellidx.com) develops and markets protein conjugates for a first-in-class multiplex immunofluorescence (mxIF) detection technology that can for the first time simultaneously detect …

Medical Writer – Carling Communications – San Diego, CA

September 15, 2017 – 4:41 pm

Writes and develops content for peer-to-peer, educational, and promotional projects for clients in the pharmaceutical and biotechnology industries….From Indeed – Sat, 16 Sep 2017 00:41:52 GMT – View all San Diego, CA jobs

Process & Extraction Operators, Food / Beverage – 2nd & 3rd shifts

September 15, 2017 – 4:03 pm

Extraction Operator – Beverages, 2nd & 3rd shift Vista, CA
Summary: The Extraction Operator extracts coffee and tea for food service orders and bulk ingredient orders ensuring the quality, brix levels and yield are being met to our standard.
Sc …

Process & Extraction Operators, Food / Beverage – 2nd & 3rd shifts

September 15, 2017 – 4:03 pm

Extraction Operator – Beverages, 2nd & 3rd shift Vista, CA
Summary: The Extraction Operator extracts coffee and tea for food service orders and bulk ingredient orders ensuring the quality, brix levels and yield are being met to our standard.
Sc …

Quality Control Stability Manager (San Diego)

September 15, 2017 – 3:54 pm

Tocagen is a clinical-stage, cancer-selective gene therapy company focused on developing first-in-class, broadly applicable product candidates designed to activate a patient’s immune system against their own cancer from within.
Every member of our t …